CSCI vs. OPTN, ELEV, DYAI, IVVD, ICCC, CELU, XLO, ACHL, KZR, and TNXP
Should you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include OptiNose (OPTN), Elevation Oncology (ELEV), Dyadic International (DYAI), Invivyd (IVVD), ImmuCell (ICCC), Celularity (CELU), Xilio Therapeutics (XLO), Achilles Therapeutics (ACHL), Kezar Life Sciences (KZR), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.
COSCIENS Biopharma vs.
OptiNose (NASDAQ:OPTN) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
OptiNose presently has a consensus price target of $16.67, indicating a potential upside of 140.33%. Given OptiNose's stronger consensus rating and higher possible upside, analysts plainly believe OptiNose is more favorable than COSCIENS Biopharma.
OptiNose has a net margin of -41.16% compared to COSCIENS Biopharma's net margin of -428.43%. OptiNose's return on equity of 0.00% beat COSCIENS Biopharma's return on equity.
OptiNose received 249 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users.
COSCIENS Biopharma has lower revenue, but higher earnings than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks.
85.6% of OptiNose shares are owned by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are owned by institutional investors. 2.3% of OptiNose shares are owned by company insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
OptiNose has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
In the previous week, OptiNose had 9 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 9 mentions for OptiNose and 0 mentions for COSCIENS Biopharma. OptiNose's average media sentiment score of 0.00 beat COSCIENS Biopharma's score of 0.00 indicating that OptiNose is being referred to more favorably in the media.
Summary
OptiNose beats COSCIENS Biopharma on 13 of the 17 factors compared between the two stocks.
Get COSCIENS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COSCIENS Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CSCI) was last updated on 1/21/2025 by MarketBeat.com Staff
